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associated with worse atrophy in DGM, hippocampus, and putamen.
Lower pallidum volume was associated with a worse score in PBA–
irritability/aggression subscale. Atrophy in ROIs such as caudate and hip-
pocampus was associated with worse cognitive performance, as evaluated
by the SDMT and VFT. Regarding manifest patients with HD, atrophy in
striatal regions was associated with worse motor symptoms. Lower vol-
umes in other subcortical ROIs such as pallidum, hippocampus, and amyg-
dala were associated with worse cognitive performance, as observed by
the scores at the SDMT, VFT, and Stroop interference test.
Conclusions: Brain atrophy is an early event in HD and antedates
motor symptoms. Brain atrophy in premanifest and manifest HD is not
restricted to the striatum, being observed in other subcortical regions as
hippocampus and amygdala. Decreased volumes in subcortical structures
are associated with behavioral/cognitive symptoms in premanifest HD
carries and with motor/cognitive symptoms in manifest patients with HD.
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NBIA-like MRI findings in a patient with Huntington’s disease
T. Shimizu, T. Matsukawa, Y. Abe, H. Suga, N. Tominaga,
M. Nagai, T. Iizuka, H. Ishiura, J. Mitsui, S. Tsuji, R. Hanajima,
K. Nishiyama (Yonago, Japan)
Objective: To report a rare case of Huntington’s disease (HD) with
MRI findings resembling neurodegeneration with brain iron accumula-
tion (NBIA).
Background: HD and NBIA are both neurodegenerative disorders that
present with cognitive decline and chorea. The neurological symptoms are
similar but brain MRI usually differentiates these two disorders; routine
brain MRI findings showing iron accumulation in the basal ganglia raises
suspicion of NBIA. Previous studies showed iron accumulation in the
brain in animal HD model, and elevated absolute iron levels in the basal
ganglia of post-mortem brain at the end-stage of HD patients as well. Fur-
thermore, MRI technique using R2 or R2* mapping has recently shown
iron deposition in the basal ganglia in HD patients. However, NBIA-like
MRI findings in HD patients on routine MRI is very rare.
Methods: Case report.
Results: A 39-year-old man was admitted to our hospital with cognitive
decline and chorea which developed since his early 30s. Brain MRI
showed atrophy of bilateral caudate and hypointensities in bilateral cau-
date, putamen, globus pallidus, substantia nigra, red nucleus and dentate
nucleus on T2WI and T2*WI. Genetic testing revealed both heterozygous
CAG repeat expansion (54/23) in the HTT gene and heterozygous p.
Lys1010Thr mutation in the exon 13 of the ATP7B gene, while serum
ceruloplasmin and urine copper levels were normal, suggesting a carrier of
Wilson’s disease. Neither known mutation nor rare variant was found in
the causative gene of NBIA1-8, aceruloplasminemia, Mucolipidosis IV
and FAHN by exome sequencing. Acanthocytosis was not identified on
peripheral blood smear. Familial history of HD in his uncle was subse-
quently confirmed.
Conclusions: We report a rare patient with HD showing NBIA-like
MRI findings. Long CAG expansion in the HTT gene or heterozygous
mutation in the ATP7B gene may be associated with these MRI findings.
Our case suggests that the presence of NBIA-like MRI finding may not
exclude the diagnosis of HD.
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A safety, tolerability and biomarker update from an ongoing open-
label extension study of RG6042 in adults with early manifest
Huntington’s disease
S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel,
G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett,
L. Boak, R. Doody, S. Schobel (London, United Kingdom)
Objective: To present the safety, tolerability and biomarker effects of
RG6042 (previously, IONIS-HTTRX) during an open-label extension
(OLE) study in adults with early manifest Huntington’s disease (HD).
Background: HD is a genetic, neurodegenerative and ultimately fatal
disease that has a devastating impact on families across generations. HD is
characterised by behavioural symptoms, as well as progressive cognitive
and motor decline, resulting in increasing disability and loss of indepen-
dence. RG6042, an intrathecally administered antisense oligonucleotide
(ASO) targeting huntingtin (HTT) mRNA, is the first investigational treat-
ment to show a dose-dependent, reversible lowering of HTT protein. Pre-
clinical models have demonstrated improved motor function and delayed
disease progression with RG6042. RG6042 was well tolerated in the
IONIS-HTTRx Phase I/IIa study in patients with early HD
(NCT02519036) and is currently being evaluated in this ongoing OLE
study (NCT03342053).
Methods: This OLE study (NCT03342053) is evaluating the long-term
safety, tolerability, pharmacokinetics and pharmacodynamics of 120mg
RG6042, administered intrathecally, monthly or bi-monthly, for 15 months
in adults (N=46) with early manifest HD (Stage I/II) who previously par-
ticipated in the Phase I/IIa study (NCT02519036). Exploratory endpoints
include assessment of standard and digital clinical outcomes, as well as
biomarkers.
Results: At the time of abstract submission, over 350 doses of RG6042
have been administered. OLE participants in the monthly regimen have
had between 8 and 15 doses of RG6042 and participants in the bi-monthly
regimen have had between 4 and 7 doses. Interim safety, tolerability and
biomarker data will be presented.
Conclusions: RG6042 is the first HTT-lowering treatment to be evalu-
ated in patients with HD. The data presented here inform on the longer-
term safety, tolerability and biomarker profile of RG6042. These data
complement other studies in the RG6042 Global Development Program
such as the RG6042 pivotal Phase III study GENERATION HD1.
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Usefulness of Heart Rate Variability to Identify the Risk of Falling in
Huntington’s Disease
C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)
Objective: To evaluate the relationship between the HRV and the risk
of falling in HD patients.
Background: Huntington’s disease (HD) patients have a high preva-
lence of falls, on the other hand, autonomic nervous system dysfunction
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has been reported from early stages of the disease. However, there is lack
of evidence regarding the relationship between heart rate variability
(HRV) and falls in this population.
Methods: Eighteen HD patients were assessed by short-term HRV
analysis EKG were recorded during 5 minutes in resting and standing
states. Time domain (MeanRR, SDNN, RMSSD), frequency domain
(VLF, LF, HF, LF/HF) and non-linear (DFA α1, DFA α2 and SampEn)
parameters were calculated. Data in each state and its difference between
were analyzed. Additionally, data regarding falls, measurements of the risk
of falling [Berg balance Scale (BBS), Timed-up go test (TUG), Tinetti
mobility test (TMT)] and specific-diseases scales were collected.
Results: The prevalence of falls was 38.9% reporting at least one or no
one fall (single faller) and 61.1% reporting two or more falls (recurrent
fallers) in the past 12 months. There was no difference in age, gender, ill-
ness duration, number of CAG repetitions, total motor score (UHDRS-
TMS), functional capacity (UHDRS-TFC) or any scale of risk of falling
between groups. Recurrent fallers had significantly lower RMSSD in rest-
ing state (p=0.020), higher LF/HF ratio in both states (resting, p = 0.011;
standing, p = 0.044) and higher DFA α1 in both states (resting, p = 0.027;
standing, p = 0.011). Patients classified with high risk of falling by BBS
in resting state showed higher power of low frequency (p=0.044) and
higher DFA α2 (p=0.011). Correlations were found in resting state
between the RMSSD and [number of falls (r=-0.486, p = 0.041), UHDRS-
TMS (r=-0.408, p = 0.030), BBS (r=0.049, p = 0.470)] and LF/HF ratio
and number of falls (r=0.539, p = 0.021)). No significant differences were
found between recurrent and single fallers for any blood pressure
measures.
Conclusions: The observed HRV pattern is consistent with a higher
sympathetic prevalence associated with a higher risk of falls. The short-
term HRV assessment is a useful and rapid tool to assess the risk of falling
in HD. The decrease of parasympathetic HRV values adequately identifies
the high risk of falling, independently of orthostatic phenomena, in this
specific population.
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Digital monitoring of Huntington’s disease with smartphone and
smartwatch wearable technology: The Digital-HD study
R. Tortelli, T. Kilchenmann, F. Rodrigues, L. Byrne, A. Bamdadian,
F. Lipsmeier, S. Schobel, M. Lindemann, E. Wild (London, United
Kingdom)
Objective: To investigate the tolerability and feasibility of using wear-
able smartphone and smartwatch technologies to monitor the motor,
behavioural, cognitive and quality of life (QoL) impact of Huntington’s
disease (HD), and generate reliable and meaningful biomarkers of disease
progression.
Background: Advances in wearable sensors and communication tech-
nologies permit unobtrusive, continuous, accurate, real-world monitoring
of chronic diseases. This has the potential to overcome many limitations
of clinic-based, intermittently administered clinical measures.
Methods: The Digital-HD study is a single-centre, prospective observa-
tional study that aims to enrol patients with manifest HD (n=40), pre-
manifest HD (n=20) and healthy controls (n=20). Data are captured from
passive monitoring and daily active tests. Passive monitoring involves
wearing a smartwatch and carrying a GPS-enabled smartphone, both con-
taining tri-axial accelerometers and gyroscopes. Active tests measure
motor and non-motor manifestations of HD, and include questions about
QoL and mood, cognitive tests, and motor tasks. Participants are trained
on active tests during an on-site equipment issue visit (EIV) and perform
these tests at home upon prompting. During the EIV, participants undergo
clinical assessments using the Unified HD Rating Scale motor, cognitive
and functional subscales, as well as the Timed-up-and-go test and selected
items from the Berg Balance Scale alongside a Kinect sensor. These in-
clinic tests are used to “anchor” the digital biomarker assessments.
Encrypted phone data are securely transferred via the internet and analysed
to extract clinically meaningful measurements for group discrimination
and correlation with clinical parameters.
Results: The study is ongoing; recruitment began in January 2019 and
will be completed by June 2019. Representative examples of digital and
in-clinic data will be presented, along with interim data on acceptability
and adherence.
Conclusions: This is the first study to compare the use of wearable
technologies for continuous monitoring in patients at various stages of HD
and healthy controls. Thanks to the high temporal and spatial resolution of
this approach, it has the potential to generate sensitive, accurate and mean-
ingful outcomes to enhance the conduct of clinical trials in HD.
*ML and EJW share senior authorship.
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Changes in GABAergic transmission of striatal neurons in
presymptomatic Huntington’s Disease
M. Treven, F. Zirpel, I. Mody (Vienna, Austria)
Objective: To determine whether parameters of synaptic and
extrasynaptic GABAergic inhibition of striatal projection neurons are
altered in presymptomatic BACHD mice.
Background: One attractive early hypothesis of HD pathogenesis was
that of a GABA deficiency disorder, with hopes for a substitution therapy
similar to levodopa for PD. While this turned out to be a drastic oversim-
plification, direct and indirect pathway striatal projection neurons (SPNs)
nevertheless require GABAergic inhibition as protection from
excitotoxicity via extensive cortical glutamatergic inputs. Mutant
huntingtin impairs receptor trafficking and surface expression, leading to
reduced surface GABAA receptors. Reduced tonic GABA currents have
been described in rapidly symptomatic R6/2 and Q175 mouse models,
likely contributing to striatal neurodegeneration. The BACHD model
employed here resembles the disease course in humans more closely, with
late onset and slow progression of motor symptoms. This allows a longitu-
dinal observation of SPN GABAergic transmission in HD.
Methods: Brain slice preparations of transgenic BACHD, asymptom-
atic Q31, and wild type FvB mice between 4 and 12 months of age were
used for voltage clamp recordings of IPSCs, EPSCs and tonic GABA cur-
rents of striatal GFP-tagged D1-SPNs and D2-SPNs.
Results: Tonic GABA currents were significantly reduced in D1- and
D2-SPNs of 4 month old presymptomatic BACHD versus control mice of
the same age (Ctrl 4M: 30.932.73 pA; BACHD 4M: 21.641.90 pA;
p = 0.0074). In contrast, parameters of phasic, synaptic GABAergic trans-
mission of SPNs (IPSC amplitudes and frequency) did not differ between
presymptomatic BACHD and control mice. Reduced SPN tonic GABA
currents in BACHD persisted into symptomatic disease stages up to
12 months of age.
Conclusions: Reduced SPN tonic GABA currents possibly contribute
to the selective vulnerability of these neurons. Our findings suggest that
these changes precede loss of neurons and disease onset. Ways of enhanc-
ing tonic GABAergic transmission in HD, via direct positive receptor
modulation or GABA reuptake blockers, might be explored to counter
excitotoxicity and delay striatal neurodegeneration.
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Novel exploratory outcome assessments in GENERATION HD1
D. Trundell, S. Schobel, R. Roos, K. Anderson, A. Thobhani,
G. Hooper, M. Nguyen, S. Tabrizi (Welwyn Garden City, United
Kingdom)
Objective: To improve collection of outcomes meaningful to patients
with Huntington’s disease (HD) and their families, through the develop-
ment of novel assessments of daily functional ability, irritability, and
speech difficulty.
Background: With an increasing focus on clinical research, there are a
number of recently developed outcome measures in HD, particularly
patient-reported outcome measures, notably the HD-PRO-TRIAD, HD-
Health Index and the FuRST 2.0. Despite these valuable additions, there is
still need for a clinician-reported outcome (ClinRO) measure of daily func-
tion that can assess change in a more granular fashion than existing
ClinROs.
With multidimensional diseases, such as HD, there is a need to measure
a broad range of symptoms and impacts. Gaps were identified while evalu-
ating the holistic measurement strategy for GENERATION HD1 against
qualitative research (indicating the core symptoms and impacts from the
perspectives of patients and their families). To balance patient burden with
the desire for comprehensive measurement, it was determined that in addi-
tion to a novel ClinRO assessing daily functional ability, brief measures of
patient-reported speech difficulty, and companion-reported irritability were
also required.
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